ST3GAL6

Across TCGA pan-cancer cohorts, ST3GAL6 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ST3GAL6 data layer compared with 20 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ST3GAL6 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ST3GAL6 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

HNSC, CCRCC, and PDAC are the cancer types where ST3GAL6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	All	0.941	0.849	.009	23	view →
CCRCC	DFS	Quartile	All	1.000	0.428	.008	8	view →
PDAC	DFS	Tertile	III,IV	1.000	0.399	.024	3	view →
GBM	DFS	Median	All	0.561	0.232	.016	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ST3GAL6–HNSC (OS)

Open the HNSC breakdown →